Indication
Secondary Progressive Multiple Sclerosis (SPMS)
Stage
Open-label, follow-on trial to MAESTRO-01
Location of Study
Canada and Europe
47 trial sites in 10 countries
Clinical Trials
MS TSX: Quote: 0.37 | Change: -0.005 | 03.18.10 | 7:50:00 MST